Maven Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

Maven Securities’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-702	Closed	-$617K	–	857
2023 Q4	$617K	Buy	702 +411	+141%	+$338K	0.01%	603
2023 Q3	$239K	Buy	+291	New	+$229K	﹤0.01%	1003
2022 Q3	–	Sell	-1,238	Closed	-$779K	–	1200
2022 Q2	$732K	Buy	1,238 +812	+191%	+$528K	0.02%	460
2022 Q1	$298K	Buy	426 +26	+7%	+$16.4K	0.01%	706
2021 Q4	$253K	Buy	+400	New	+$246K	0.01%	733
2021 Q2	–	Sell	-520	Closed	-$263K	–	1284
2021 Q1	$246K	Sell	520 -1,078	-67%	-$525K	0.01%	871
2020 Q4	$772K	Buy	1,598 +616	+63%	+$333K	0.08%	284
2020 Q3	$557K	Buy	982 +610	+164%	+$370K	0.05%	359
2020 Q2	$232K	Buy	+372	New	+$211K	0.02%	475

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Maven Securities's REGN Position: Q1 2024 in Review

Maven Securities sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 702 shares — an estimated $617K sold.

Maven Securities first reported a position in REGN in Q2 2020 and held it in 9 quarters. The position peaked at $772K in Q4 2020. 1,312 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Maven Securities reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Maven Securities sold 702 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $617K.
Maven Securities first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Maven Securities's Regeneron Pharmaceuticals position peaked at $772K in Q4 2020.
1,312 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Maven Securities's 13F filing for Q1 2024, filed 14 May 2024.